Neurocrine Biosciences Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Neurocrine Biosciences de 23.1% y 11.8% por año respectivamente. Se prevé que el BPA crezca en un 21.6% al año. Se espera que la rentabilidad financiera sea de 20.9% en 3 años.
Información clave
23.1%
Tasa de crecimiento de los beneficios
21.59%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 25.1% |
| Tasa de crecimiento de los ingresos | 11.8% |
| Rentabilidad financiera futura | 20.95% |
| Cobertura de analistas | Good |
| Última actualización | 29 Jun 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Seeking Alpha • 2h
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno
Summary Neurocrine Biosciences, Inc. remains a Buy, driven by robust growth from Ingrezza, Crenessity, and the recent Vykat acquisition. Q1 2026 revenues rose 44% year-on-year to $811m, with Ingrezza and Crenessity annualizing at blockbuster levels and Vykat showing rapid ramp-up. NBIX stock valuation reflects high-growth expectations; forward P/S ~5.1x and P/E ~30x, justified by an expanding commercial portfolio and pipeline catalysts. Patent protection through 2038 for Ingrezza and solid balance sheet support long-term growth, with pipeline approvals offering further upside potential. Read the full article on Seeking Alpha
Actualización de narrativa • Jun 24
NBIX: Future Upside Will Rely On Expanding Rare Disease Franchise
Analysts have nudged their price target for Neurocrine Biosciences higher to $243.06 from $241.76, citing updated views on revenue growth, profit margins, and future P/E expectations following recent coverage initiations and the addition of Soleno Therapeutics' Vykat XR to the portfolio. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a generally constructive tone, with several firms updating views on the stock following the completion of the Soleno Therapeutics acquisition and fresh coverage initiations.Artículo de análisis • Jun 19
Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data
Neurocrine Biosciences (NBIX) is in focus after new CRENESSITY data at ENDO 2026 highlighted hormone normalization in classic CAH due to 11ß hydroxylase deficiency, alongside two-year cardiometabolic and bone health outcomes in adults. See our latest analysis for Neurocrine Biosciences. At a share price of $158.29, Neurocrine Biosciences has given investors a 23.97% 90 day share price return and a 25.08% 1 year total shareholder return, pointing to momentum that has built alongside ENDO 2026...
Actualización de narrativa • Jun 09
NBIX: Future Upside Will Depend On Rare Disease Portfolio Execution
Analysts have lifted the fair value estimate for Neurocrine Biosciences by about $6 to $192.88, reflecting updated views on revenue growth, profitability and valuation after the Soleno acquisition, along with recent Street research highlighting a long runway for key drugs and additional contributions from Vykat XR. Analyst Commentary Recent Street research around Neurocrine Biosciences has been broadly constructive, with several firms updating models after the Soleno acquisition and new readthroughs on key products.
Actualización de narrativa • May 26
NBIX: Pipeline Execution And Integration Risks Will Shape Balanced Future Returns
Analysts lifted their fair value target for Neurocrine Biosciences by about $3 to $144, citing updated assumptions for revenue growth of 14.83%, a profit margin of 18.43%, and a recalibrated future P/E of 21.28x that reflects confidence in the long runway of its key approved drugs and potential contributions from Crenessity and osavampator. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a mix of optimism around the company’s approved therapies and emerging pipeline, alongside selective caution on execution and valuation.Artículo de análisis • May 08
Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next
Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...Actualización de narrativa • May 07
NBIX: Future Upside Will Depend On Execution Across Two Core Franchises
The updated analyst price target for Neurocrine Biosciences moves to $241.76 from $203.91, with analysts pointing to higher modeled revenue growth and slightly richer future P/E assumptions, partly balanced by a modestly lower profit margin outlook and a small change in the discount rate. Analyst Commentary Recent Street research on Neurocrine Biosciences shows a cluster of price target changes and fresh coverage that tilt bullish overall, even with a few modest trims.Actualización de narrativa • Apr 21
NBIX: Future Upside Will Hinge On Tardive Dyskinesia Franchise Execution
The updated analyst price target for Neurocrine Biosciences increases to $186.45 from $178.04. Analysts attribute the change to more supportive long-term earnings expectations and higher assumed future P/E multiples, even as they refine revenue growth and margin assumptions.Actualización de narrativa • Apr 07
NBIX: Mixed 2026 Guidance And Policy Risks Will Shape Future Returns
Analysts have made a small upward adjustment to the fair value estimate for Neurocrine Biosciences to about $140.54, reflecting updated price targets that weigh mixed revisions across the Street against generally constructive views on Ingrezza and Crenessity. Analyst Commentary Street research around Neurocrine Biosciences has been active, with a mix of supportive views on key assets like Ingrezza and Crenessity and a series of price target tweaks that pull in different directions.Actualización de narrativa • Mar 24
NBIX: Future Upside Will Depend On Crenessity Adoption And Pipeline Progress
Analysts have trimmed the blended price target for Neurocrine Biosciences slightly to about $178, reflecting modest tweaks to growth, discount rate and P/E assumptions, while incorporating mixed but generally constructive views on Ingrezza and Crenessity uptake from recent research updates. Analyst Commentary Street research on Neurocrine Biosciences has been active, with several firms adjusting price targets and models around recent earnings, updated guidance and new information on Ingrezza and Crenessity.Actualización de narrativa • Mar 09
NBIX: 2026 Guidance Execution And CAH Competition Will Shape Future Returns
Analysts have kept the fair value estimate for Neurocrine Biosciences steady at $140, while revising their models slightly to reflect updated revenue growth, margins, and P/E assumptions following recent earnings, guidance, and a mix of modest price target cuts and a fresh $160 Outperform initiation. Analyst Commentary Across recent research, you are seeing a mix of optimism around the pipeline and commercial assets along with a cluster of more cautious valuation resets.Actualización de narrativa • Feb 23
NBIX: Execution On 2026 Guidance And Competitive CAH Data Will Shape Outlook
Neurocrine Biosciences' updated analyst price target of $140.00, down from $169.00, reflects refreshed models after Q4 results and 2026 guidance, with analysts still pointing to Ingrezza and Crenessity as key drivers in their long term assumptions despite recent target trims across the Street. Analyst Commentary Street research around Neurocrine Biosciences has turned more mixed, with several bearish analysts trimming price targets following Q4 results and updated 2026 guidance, while a few others have made only modest upward adjustments.Actualización de narrativa • Feb 09
NBIX: Future Returns Will Hinge On Crenessity Execution And Pipeline Delivery
Analysts made a modest trim to their Neurocrine Biosciences price targets, generally landing around the high US$170s. Updated models reflect slightly more conservative revenue growth assumptions and a marginally higher discount rate, partly offset by steady margin expectations and supportive views on Crenessity and Ingrezza.Actualización de narrativa • Jan 24
NBIX: Future Revenue Will Depend On Execution Across Two Key Franchises
Analysts have raised their fair value estimate for Neurocrine Biosciences to about US$204 from US$192. This reflects updated assumptions that include slightly stronger revenue growth, higher profit margins and a lower future P/E multiple after recent Street research refined expectations for Ingrezza, Crenessity and competitor dynamics.Actualización de narrativa • Jan 10
NBIX: Commercial Execution And Pipeline Progress Will Drive Future Shareholder Returns
Analysts have raised their fair value estimate for Neurocrine Biosciences from about $177.92 to $179.66, reflecting updated models that incorporate recent price target revisions, current product performance, and expectations regarding future competition and commercial execution. Analyst Commentary Recent research updates show a mix of optimism and caution around Neurocrine Biosciences, with most price target moves clustering around the high $160s to mid $180s and reflecting updated models on current products, competitive developments in congenital adrenal hyperplasia, and spending to support commercial execution.Actualización de narrativa • Dec 17
NBIX: Advancing CNS Pipeline Readouts Will Drive Future Shareholder Returns
Analysts have modestly increased their average price target for Neurocrine Biosciences by about $3, to roughly $178, citing stronger than expected product performance, sustained Ingrezza growth momentum, and growing confidence in the company’s advancing pipeline despite potential IRA related pricing headwinds. Analyst Commentary Street research remains broadly constructive on Neurocrine, with multiple firms nudging price targets higher as they factor in stronger execution, commercial visibility for Ingrezza and Crenessity, and a maturing late stage pipeline.Actualización de narrativa • Dec 03
NBIX: Late-Stage CNS Pipeline Readouts Will Drive Future Shareholder Value
Analysts have nudged their blended price target for Neurocrine Biosciences modestly higher to the high $170s to low $180s range, reflecting stronger than expected Ingrezza and Crenessity performance, confidence in commercial execution ahead of IRA related headwinds, and growing optimism around the longer term pipeline. Analyst Commentary Bullish analysts largely frame the recent pullback as a mismatch between robust fundamentals and short term market sentiment, with multiple firms lifting price targets into the mid $160s to mid $190s range even as shares consolidated.Actualización de narrativa • Nov 19
NBIX: Late-Stage Pipeline Advancements Will Drive Shareholder Value Amid Industry Headwinds
Neurocrine Biosciences' analyst price target has increased modestly, up by $3 to $174. Analysts cite ongoing strong commercial performance, expanded sales force initiatives, and a robust late-stage pipeline as supporting factors for sustained growth potential.Actualización de narrativa • Nov 05
NBIX: Expanding Commercial Momentum And Pipeline Advances Will Drive Shareholder Value
The analyst price target for Neurocrine Biosciences has been raised from approximately $170 to $175 per share. This reflects analyst optimism about the company’s strong recent earnings, expanded sales efforts, and ongoing commercial and pipeline momentum.Actualización de narrativa • Oct 22
Analysts Boost Neurocrine Biosciences Price Target Citing Strong Revenue Outlook and Clinical Results
Analysts have raised their price target for Neurocrine Biosciences from $168.25 to $169.95. They cite stronger revenue outlooks for key products and supportive recent clinical trial data as the main reasons for this adjustment.Seeking Alpha • Apr 22
Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025
Summary Company's valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in 2025, targeting patients unresponsive to antipsychotics. The company also anticipates phase 3 data for valbenazine in treating dyskinetic cerebral palsy in 2025, presenting another market opportunity. Neurocrine's financial health is robust, with $1.8 billion in cash and strong revenue growth from INGREZZA, which saw a 23% year-over-year increase in Q4 2024. The Schizophrenia market across the 7 major markets is expected to reach $17 billion by 2031. Read the full article on Seeking AlphaPrevisiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 5,010 | 1,408 | 1,757 | 1,864 | 18 |
| 12/31/2027 | 4,476 | 1,090 | 1,376 | 1,424 | 21 |
| 12/31/2026 | 3,773 | 542 | 930 | 717 | 22 |
| 3/31/2026 | 3,102 | 669 | 831 | 864 | N/A |
| 12/31/2025 | 2,861 | 479 | 749 | 783 | N/A |
| 9/30/2025 | 2,683 | 428 | 593 | 637 | N/A |
| 6/30/2025 | 2,510 | 348 | 529 | 567 | N/A |
| 3/31/2025 | 2,413 | 306 | 492 | 530 | N/A |
| 12/31/2024 | 2,355 | 341 | 557 | 595 | N/A |
| 9/30/2024 | 2,243 | 386 | 440 | 476 | N/A |
| 6/30/2024 | 2,120 | 339 | 495 | 530 | N/A |
| 3/31/2024 | 1,982 | 370 | 614 | 645 | N/A |
| 12/31/2023 | 1,887 | 250 | 362 | 390 | N/A |
| 9/30/2023 | 1,784 | 191 | 385 | 409 | N/A |
| 6/30/2023 | 1,673 | 176 | 281 | 296 | N/A |
| 3/31/2023 | 1,599 | 64 | 237 | 255 | N/A |
| 12/31/2022 | 1,489 | 155 | 323 | 339 | N/A |
| 9/30/2022 | 1,389 | 58 | 177 | 201 | N/A |
| 6/30/2022 | 1,297 | 12 | 133 | 164 | N/A |
| 3/31/2022 | 1,208 | 71 | 102 | 129 | N/A |
| 12/31/2021 | 1,134 | 90 | 233 | 257 | N/A |
| 9/30/2021 | 1,069 | 445 | 328 | 347 | N/A |
| 6/30/2021 | 1,032 | 365 | 251 | 265 | N/A |
| 3/31/2021 | 1,045 | 402 | 266 | 280 | N/A |
| 12/31/2020 | 1,046 | 407 | 218 | 229 | N/A |
| 9/30/2020 | 1,042 | 93 | 222 | 232 | N/A |
| 6/30/2020 | 1,006 | 205 | 337 | 350 | N/A |
| 3/31/2020 | 887 | 177 | 283 | 295 | N/A |
| 12/31/2019 | 788 | 37 | N/A | 147 | N/A |
| 9/30/2019 | 675 | 21 | N/A | 100 | N/A |
| 6/30/2019 | 605 | 18 | N/A | 71 | N/A |
| 3/31/2019 | 519 | -39 | N/A | 27 | N/A |
| 12/31/2018 | 451 | 21 | N/A | 101 | N/A |
| 9/30/2018 | 414 | 10 | N/A | 91 | N/A |
| 6/30/2018 | 323 | -52 | N/A | 13 | N/A |
| 3/31/2018 | 233 | -106 | N/A | -55 | N/A |
| 12/31/2017 | 162 | -143 | N/A | -94 | N/A |
| 9/30/2017 | 67 | -194 | N/A | -167 | N/A |
| 6/30/2017 | 6 | -220 | N/A | -188 | N/A |
| 3/31/2017 | N/A | -200 | N/A | -154 | N/A |
| 12/31/2016 | 15 | -141 | N/A | -106 | N/A |
| 9/30/2016 | 15 | -126 | N/A | -90 | N/A |
| 6/30/2016 | 15 | -123 | N/A | -77 | N/A |
| 3/31/2016 | 15 | -107 | N/A | -49 | N/A |
| 12/31/2015 | 20 | -89 | N/A | -38 | N/A |
| 9/30/2015 | 20 | -79 | N/A | -38 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (23.1% al año) de NBIX es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (23.1% al año) de NBIX crezcan más rápidamente que el mercado US (18.8% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de NBIX crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (11.8% al año) de NBIX crezcan más despacio que el mercado de US (12.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 11.8% al año) de NBIX crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de NBIX sea alta dentro de 3 años (20.9%)
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/02 21:36 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Neurocrine Biosciences, Inc. está cubierta por 39 analistas. 22 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Martha Freitag | Argus Research Company |
| Brian Skorney | Baird |
| Aydin Huseynov | Benchmark Company |